Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Trial of bNAbs or ATI in Early Treated Children with HIV in Botswana
NCT06508749Phase 2Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2024
- Primary completion
- Sep 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of PGDM1400LS, VRC07-523LS, PGT121 in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2024; status: active, not recruiting.
02
Drugs
PGDM1400LSVRC07-523LSPGT121
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06508749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508749.